Day 4 Recap: AAD 2026

To stay informed with the latest conference insights, follow us on LinkedIn, Facebook, X, and Instagram, and subscribe to receive our eNewsletters.

Defining High-Risk NMSC: Integrating Staging Systems and Tumor Biology to Guide Management

At AAD 2026, Todd Schlesinger, MD, highlighted how staging frameworks and clinicopathologic features can inform treatment decisions in nonmelanoma skin cancer.

Bimekizumab Maintains Clinical Response in HS Across Subgroups at 3 Years

Three-year BE HEARD EXT data confirm that bimekizumab's clinical responses deepen over time, with HiSCR90 rates rising from 42% at year 1 to 64% at year 3.

Topical Steroid Withdrawal Syndrome: What Dermatologists Need to Know About Diagnosis and Management

Maria-Angeliki Gkini, MD, PhD, shared guidance on diagnosing and managing topical steroid withdrawal syndrome.

Zasocitinib Phase 3 Data Demonstrate Rapid, Durable Skin Clearance in Plaque Psoriasis

Christopher Bunick, MD, PhD, and Chinweike Ukomadu, MD, PhD, discuss late-breaking phase 3 findings highlighting high rates of clearance and favorable safety with once-daily oral zasocitinib.

Pediatric Allergic Contact Dermatitis: Screening, Allergens, and Why Diagnosis Changes Everything

Jeff Yu, MD, discusses important issues in screening and addressing pediatric contact dermatitis at the AAD Annual Meeting.

Izokibep Shows Sustained Phase 3 HiSCR Response in Biologic-Naïve and Experienced HS Patients

The small protein therapeutic gave hidradenitis suppurativa patients greater reductions in inflammatory lesion counts after 32 weeks.

Allergan Presents New Phase 3 TrenibotE Data and GLP-1 Patient Insights at AAD 2026

Posters from Allergan Aesthetics highlight the efficacy of investigational trenibotulinumtoxinE, along with new aesthetic trends in GLP-1 users.